Αρχική World News Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients with...

Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients with Early Stage Colon Cancer

The Immunoscore assay can assess the risk of recurrance in early stage colon cancer and may be used together with TNM classification to guide clinical decision-making, according to findings presented at the ESMO Asia Virtual Congress 2020, held 20 to 22 November 2020.

Jérôme Galon of the Cordeliers Research Center, INSERM team 15, Laboratory of Integrative Cancer Immunology in Paris, France, reported how Immunoscore, an in vitro diagnostic test, may be used to predict the risk of relapse in early‐stage colon cancer by measuring the patient’s immune response at the tumour site. He explained that the risk‐assessment tool has been shown to provide independent prognostic value that is superior to the usual risk parametres and is intended for use as an adjunct to the TNM classification for clinical decision.  

Professor Galon and colleagues conducted this study to evaluate the clinical performance of Immunoscore in an Asian population using data from the Society for Immunotherapy of Cancer (SITC)-led validation study, wherein 423 patients of the 2681 eligible stage I-III patients enrolled in the international Immunoscore study1 were recruited from 4 expert centres. Specifically, 330 patients were enrolled from Japan, 35 from China, and 58 patients were from India.

The investigators compared the time to recurrence (TTR) according to Immunoscore categories. Patient classification by Immunoscore (IS) was done using pre-defined cut-offs: IS Low (IS 0-1) and IS High (IS 2-4).

A significant positive association was found between Immunoscore and TTR in the Asian subgroup that was consistent with data from the entire study population

In the Asian cohort, 158 (37%) patients were categorised as Immunoscore Low and and 266 (63%) were categorised as Immunoscore High.

At 5 years, 86.9% (95% confidence interval  [CI] 82.7-91.4), of Immunoscore High patients were event-free compared to 77% (95% CI 70,5-84,1) of Immunoscore Low patients (hazard ratio [HR] 0.52; 95% CI 0.32-0.86; p = 0.0085).

Furthermore, with model adjustments including Immunoscore, age, gender, T-stage, N-stage, sidedness and micro-sattelite instability (MSI), and stratification by centre, Immunoscore maintained this asociation (HR 0.45; 95% CI 0.22-0.91; p = 0.027). When stratified according to the 5 Immunoscore categories (high to low), the 5-year

TTR rates were 100%, 96%, 84%, 80%, and 73.5% for IS4, IS3, IS2, IS1, IS0, respectively.

Conclusions

The authors noted that these results were similar to those found in European and North American patients.

They further concluded that Immunoscore is a strong prognostic indicator of the risk of recurrence in stage I-III colon cancer patients who receive standard of care treatment in real-life clinical practice in Asia, and suggest that this first standardised immune-based assay risk assessment tool can be used reliably to guide clinical decision according to each patient’s information.

Immunoscore-Classification-Significantly-Associates-with-Time-to-Recurrance-In-Asian-Patients-with-Early-Stage-Colon-Cancer

The prognostic value of Immunoscore and its predictive value of response to chemotherapy has been shown in multiple published studies. Immunoscore is also associated with time to recurrence and overall survival in the Asian population. The clinical utility of Immunoscore has been demonstrated and Immunoscore has been included into the WHO digestive cancer classification and into the ESMO clinical guidelines for gastrointestinal tumours in 2020. It has not yet been included into Asian and Japanese guidelines.

© Jérôme Galon.

This study was funded by the French National Institute of Health and Medical Research (INSERM), the LabEx Immuno-oncology, the Transcan ERAnet Immunoscore European project, Association pour la Recherche contre le Cancer, CARPEM, AP-HP, Institut National du Cancer, Italian Association for Cancer Research, national grants and the SITC. Immunoscore® is a registered trademark from the INSERM licensed to HalioDx.

Citation

  1. Pagès F, et al. The Lancet 2018;391(10135):2128-2139. 

Reference

79O – Galon J, Kawakami Y, Torigoe T, et al. Clinical performance of Immunoscore in early colon cancer in the Asian population. ESMO Asia Virtual Congress 2020 (20-22 November).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

On 24 November 2020, the US Food and Drug Administration (FDA) granted accelerated approval to naxitamab (DANYELZA, Y-mAbs Therapeutics, Inc.) in combination with granulocyte-macrophage...

Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead to Fewer Cases

Many women may wonder if they have genetic mutations that make them more apt to develop breast and ovarian cancers. Is it worth it...

After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby

At 31-years-old, and during the week of her daughter’s first birthday, Gemma Isaacs received shocking news. Not only did her doctor confirm that she...

“Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast Cancer

Hollie Jobber spent her life protecting and caring for children, both her own and those most in need. The 35-year-old mother of five worked...

Spending Review 2020 – Steps in the right direction, but opportunities missed

Today, the Chancellor Rishi Sunak set out the UK Government’s spending priorities for the next year. It was an opportunity to lay the groundwork for...

Coping With the Holidays During COVID-19 and Cancer

As we prepare for the holidays this year, we face a new challenge that forces us to rethink plans and possibly even cancel them....